JAZZ vs KALV · P/E 1988, rev $2.28B vs rev $13.7M
Jazz Pharmaceuticals PLC (JAZZ) versus Kalvista Pharmaceuticals Inc (KALV) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. KALV currently screens at market cap $1.44B.
Not investment advice. Open the JAZZ and KALV stock pages for the full models.
Not investment advice.